This strategy was adopted for the treatment of a murine model of prostate cancer wherein a helper virus–free HSV-1 amplicon expressing the prostate-specific antigen (HSV-PSA), which is a tumor antigen specifically expressed by prostate epithelial and carcinoma cells, was shown to be efficient in transducing dendritic cells (DCs) and processing the tumor antigen for MHC class II presentation to CTL [121]. This evidence concerns the gene KLK3 and carcinoma.